Download PDF
Semin Reprod Med 2002; 20(4): 349-364
DOI: 10.1055/s-2002-36713
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

GnRH Agonists, Antagonists, and Assisted Conception

André C.D. van Loenen, Judith A.F. Huirne, Roel Schats, Peter G.A. Hompes, Cornelis B. Lambalk
  • Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Vrije Universiteit Medical Centre (VUMC), Amsterdam, The Netherlands
Further Information

Publication History

Publication Date:
21 January 2003 (online)

    Permissions and Reprints

ABSTRACT

Pituitary stimulation with pulsatile gonadotropin-releasing hormone (GnRH) induces both follicle-stimulating hormone and luteinizing hormone (LH). Blockade of pituitary gonadotropin secretion occurs upon desensitization when a continuous GnRH stimulus is provided by means an agonist or when the pituitary receptors are occupied with a competitive antagonist. The most common indication for blockade of pituitary gonadotropin secretion is with assisted reproduction treatment (ART) where it prevents premature luteinization. Originally by lack of clinically available GnRH antagonist, prolonged daily injection of agonist with its desensitizing effect was introduced for this purpose. Today, single- and multiple-dose injectable antagonists are also available to block the LH surge. This review provides an overview of the use of GnRH agonists and antagonists in assisted reproduction.

KEYWORD

GnRH - agonist - antagonist - assisted reproduction - IVF - IUI

REFERENCES

  • 1 Edwards R G. The history of assisted human conception with especial reference to endocrinology.  Exp Clin Endocrinol Diabetes . 1996;  104 183-204
    PubMedGoogle Scholar
  • 2 Janssens R M, Lambalk C B, Vermeiden J P. Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study.  Hum Reprod . 2000;  15 2333-2340
    CrossrefPubMedGoogle Scholar
  • 3 Templeton A, Morris J K. Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization.  N Engl J Med . 1998;  339 573-577
    CrossrefPubMedGoogle Scholar
  • 4 Porter R N, Smith W, Craft I L, Abdulwahid N A, Jacobs H S. Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins.  Lancet . 1984;  2 1284-1285
    PubMedGoogle Scholar
  • 5 Schally A V, Nair R M, Redding T W, Arimura A. Isolation of the luteinizing hormone and follicle-stimulating hormone-releasing hormone from porcine hypothalami.  J Biol Chem . 1971;  246 7230-7236
    PubMedGoogle Scholar
  • 6 Amos M, Burgus R, Blackwell R, Vale W, Fellows R, Guillemin R. Purification, amino acid composition and N-terminus of the hypothalamic luteinizing hormone releasing factor (LRF) of bovine origin.  Biochem Biophys Res Commun . 1971;  44 205-210
    CrossrefPubMedGoogle Scholar
  • 7 Sealfon S C, Weinstein H, Millar R P. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor.  Endocr Rev . 1997;  18 180-205
    CrossrefPubMedGoogle Scholar
  • 8 Yahalom D, Chen A, Ben Aroya N. The gonadotropin-releasing hormone family of neuropeptides in the brain of human, bovine and rat: identification of a third isoform.  FEBS Lett . 1999;  463 289-294
    CrossrefPubMedGoogle Scholar
  • 9 Yang-Feng T L, Seeburg P H, Francke U. Human luteinizing hormone-releasing hormone gene (LHRH) is located on short arm of chromosome 8 (region 8p11.2-p21).  Somat Cell Mol Genet . 1986;  12 95-100
    PubMedGoogle Scholar
  • 10 White R B, Eisen J A, Kasten T L, Fernald R D. Second gene for gonadotropin-releasing hormone in humans.  Proc Natl Acad Sci U S A . 1998;  95 305-309
    CrossrefPubMedGoogle Scholar
  • 11 Probst J C, Skutella T, Muller-Schmid A, Jirikowski G F, Hoffmann W. Molecular and cellular analysis of rP1.B in the rat hypothalamus: in situ hybridization and immunohistochemistry of a new P-domain neuropeptide.  Brain Res Mol Brain Res . 1995;  33 269-276
    PubMedGoogle Scholar
  • 12 Kottler M L, Lorenzo F, Bergametti F, Commercon P, Souchier C, Counis R. Subregional mapping of the human gonadotropin-releasing hormone receptor (GnRH-R) gene to 4q between the markers D4S392 and D4S409.  Hum Genet . 1995;  96 477-480
    PubMedGoogle Scholar
  • 13 Millar R, Lowe S, Conklin D. A novel mammalian receptor for the evolutionarily conserved type II GnRH.  Proc Natl Acad Sci U S A . 2001;  98 9636-9641
    CrossrefPubMedGoogle Scholar
  • 14 Neill J D, Duck L W, Sellers J C, Musgrove L C. A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates.  Biochem Biophys Res Commun . 2001;  282 1012-1018
    CrossrefPubMedGoogle Scholar
  • 15 Janssens R M, Brus L, Cahill D J, Huirne J A, Schoemaker J, Lambalk C B. Direct ovarian effects and safety aspects of GnRH agonists and antagonists.  Hum Reprod Update . 2000;  6 505-518
    CrossrefPubMedGoogle Scholar
  • 16 Stojilkovic S S, Reinhart J, Catt K J. Gonadotropin-releasing hormone receptors: structure and signal transduction pathways.  Endocr Rev . 1994;  15 462-499
    CrossrefPubMedGoogle Scholar
  • 17 Kaiser U B, Conn P M, Chin W W. Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines.  Endocr Rev . 1997;  18 46-70
    CrossrefPubMedGoogle Scholar
  • 18 Conn P M, Crowley Jr F W. Gonadotropin-releasing hormone and its analogs.  Annu Rev Med . 1994;  45 391-405
    CrossrefPubMedGoogle Scholar
  • 19 Karten M J, Rivier J E. Gonadotropin-releasing hormone analog design-structure-function studies toward the development of agonists and antagonists: rationale and perspective.  Endocr Rev . 1986;  7 44-66
    PubMedGoogle Scholar
  • 20 Huirne J AF, Lambalk C B. Gonadotropin-releasing-hormone-receptor antagonists.  Lancet . 2001;  358 1793-1803
    CrossrefPubMedGoogle Scholar
  • 21 Schally A V. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis.  Peptides . 1999;  20 1247-1262
    CrossrefPubMedGoogle Scholar
  • 22 Bajusz S, Kovacs M, Gazdag M. Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects.  Proc Natl Acad Sci U S A . 1988;  85 1637-1641
    PubMedGoogle Scholar
  • 23 Ljungqvist A, Feng D M, Hook W, Shen Z X, Bowers C, Folkers K. Antide and related antagonists of luteinizing hormone release with long action and oral activity.  Proc Natl Acad Sci U S A . 1988;  85 8236-8240
    PubMedGoogle Scholar
  • 24 Rivier J, Porter J, Hoeger C. Gonadotropin-releasing hormone antagonists with N omega-triazolylornithine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6.  J Med Chem . 1992;  35 4270-4278
    CrossrefPubMedGoogle Scholar
  • 25 Nestor Jr J J, Tahilramani R, Ho T L, Goodpasture J C, Vickery B H, Ferrandon P. Potent gonadotropin releasing hormone antagonists with low histamine-releasing activity.  J Med Chem . 1992;  35 3942-3948
    CrossrefPubMedGoogle Scholar
  • 26 Garnick M B, Campion M. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group.  Mol Urol . 2000;  4 275-277
    PubMedGoogle Scholar
  • 27 Cook T, Sheridan W P. Development of GnRH antagonists for prostate cancer: new approaches to treatment.  Oncologist . 2000;  5 162-168
    CrossrefPubMedGoogle Scholar
  • 28 Brus L, Lambalk C B, de Koning J, Helder M N, Janssens R M, Schoemaker J. Specific gonadotrophin-releasing hormone analogue binding predominantly in human luteinized follicular aspirates and not in human pre-ovulatory follicles.  Hum Reprod . 1997;  12 769-773
    CrossrefPubMedGoogle Scholar
  • 29 Raga F, Casan E M, Kruessel J, Wen Y, Bonilla-Musoles F, Polan M L. The role of gonadotropin-releasing hormone in murine preimplantation embryonic development.  Endocrinology . 1999;  140 3705-3712
    CrossrefPubMedGoogle Scholar
  • 30 Lahat E, Raziel A, Friedler S, Schieber-Kazir M, Ron-El R. Long-term follow-up of children born after inadvertent administration of a gonadotrophin-releasing hormone agonist in early pregnancy.  Hum Reprod . 1999;  14 2656-2660
    CrossrefPubMedGoogle Scholar
  • 31 The Ganirelix Dose-Finding Study Group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon).  Hum Reprod . 1990;  13 3023-3031
    PubMedGoogle Scholar
  • 32 Kol S, Lightman A, Hillensjo T. High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles.  Hum Reprod . 1999;  14 2242-2244
    CrossrefPubMedGoogle Scholar
  • 33 Anik S T, McRae G, Nerenberg C. Nasal absorption of nafarelin acetate, the decapeptide [D-Nal 6)]LHRH, in rhesus monkeys I.  J Pharm Sci . 1984;  73 684-685
    PubMedGoogle Scholar
  • 34 Holland F J, Fishman L, Costigan D C, Luna L, Leeder S. Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10 luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty.  J Clin Endocrinol Metab . 1986;  63 1065-1070
    PubMedGoogle Scholar
  • 35 Broekmans F J, Bernardus R E, Berkhout G, Schoemaker J. Pituitary and ovarian suppression after early follicular and mid-luteal administration of a LHRH agonist in a depot formulation: decapeptyl CR.  Gynecol Endocrinol . 1992;  6 153-161
    PubMedGoogle Scholar
  • 36 Porcu E, Dal Prato L, Seracchioli R, Fabbri R, Longhi M, Flamigni C. Comparison between depot and standard release triptoreline in in vitro fertilization: pituitary sensitivity, luteal function, pregnancy outcome, and perinatal results.  Fertil Steril . 1994;  62 126-132
    PubMedGoogle Scholar
  • 37 Porcu E, Filicori M, Dal Prato L. Comparison between depot leuprorelin and daily buserelin in IVF.  J Assist Reprod Genet . 1995;  12 15-19
    PubMedGoogle Scholar
  • 38 Devreker F, Govaerts I, Bertrand E, van den M B, Gervy C, Englert Y. The long-acting gonadotropin-releasing hormone analogues impaired the implantation rate.  Fertil Steril . 1996;  65 122-126
    PubMedGoogle Scholar
  • 39 Fujii S, Sato S, Fukui A, Kimura H, Kasai G, Saito Y. Continuous administration of gonadotrophin-releasing hormone agonist during the luteal phase in IVF.  Hum Reprod . 2001;  16 1671-1675
    CrossrefPubMedGoogle Scholar
  • 40 Oppenheim D S, Bikkal H, Crowley Jr F W, Klibanski A. Effects of chronic GnRH analogue administration on gonadotrophin and alpha-subunit secretion in post-menopausal women.  Clin Endocrinol (Oxf) . 1992;  36 559-564
    PubMedGoogle Scholar
  • 41 Winslow K L, Gordon K, Williams R F, Hodgen G D. Interval required for gonadotropin-releasing hormone-agonist-induced down regulation of the pituitary in cynomolgus monkeys and duration of the refractory state.  Fertil Steril . 1992;  58 1209-1214
    PubMedGoogle Scholar
  • 42 Sungurtekin U, Jansen R P. Profound luteinizing hormone suppression after stopping the gonadotropin-releasing hormone-agonist leuprolide acetate.  Fertil Steril . 1995;  63 663-665
    PubMedGoogle Scholar
  • 43 Fujii S, Sagara M, Kudo H, Kagiya A, Sato S, Saito Y. A prospective randomized comparison between long and discontinuous-long protocols of gonadotropin-releasing hormone agonist for in vitro fertilization.  Fertil Steril . 1997;  67 1166-1168
    CrossrefPubMedGoogle Scholar
  • 44 Klein K O, Barnes K M, Jones J V, Feuillan P P, Cutler Jr B G. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience.  J Clin Endocrinol Metab . 2001;  86 4711-4716
    CrossrefPubMedGoogle Scholar
  • 45 Oerter K E, Manasco P, Barnes K M, Jones J, Hill S, Cutler Jr B G. Adult height in precocious puberty after long-term treatment with deslorelin.  J Clin Endocrinol Metab . 1991;  73 1235-1240
    PubMedGoogle Scholar
  • 46 Palmert M R, Mansfield M J, Crowley Jr F W, Crigler Jr F J, Crawford J D, Boepple P A. Is obesity an outcome of gonadotropin-releasing hormone agonist administration?.  <~>Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab . 1999;  84 4480-4488
    PubMedGoogle Scholar
  • 47 Schlegel P N, Kuzma P, Frick J. Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin.  Urology . 2001;  58 578-582
    CrossrefPubMedGoogle Scholar
  • 48 Chertin B, Spitz I M, Lindenberg T. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.  J Urol . 2000;  163 838-844
    PubMedGoogle Scholar
  • 49 Spitz I M, Chertin B, Lindenberg T, Farkas A. Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer [letter].  N Engl J Med . 1999;  340 1439
    CrossrefPubMedGoogle Scholar
  • 50 Gonen Y, Dirnfeld M, Goldman S, Koifman M, Abramovici H. The use of long-acting gonadotropin-releasing hormone agonist (GnRH-a; decapeptyl) and gonadotropins versus short-acting GnRH-a (buserelin) and gonadotropins before and during ovarian stimulation for in vitro fertilization (IVF).  J In Vitro Fert Embryo Transf . 1991;  8 254-259
    PubMedGoogle Scholar
  • 51 Balasch J, Jove I C, Moreno V, Civico S, Puerto B, Vanrell J A. The comparison of two gonadotropin-releasing hormone agonists in an in vitro fertilization program.  Fertil Steril . 1992;  58 991-994
    PubMedGoogle Scholar
  • 52 Penzias A S, Shamma F N, Gutmann J N, Jones E E, DeCherney A H, Lavy G. Nafarelin versus leuprolide in ovulation induction for in vitro fertilization: a randomized clinical trial.  Obstet Gynecol . 1992;  79 739-742
    PubMedGoogle Scholar
  • 53 Tapanainen J, Hovatta O, Juntunen K. Subcutaneous goserelin versus intranasal buserelin for pituitary down-regulation in patients undergoing IVF: a randomized comparative study.  Hum Reprod . 1993;  8 2052-2055
    PubMedGoogle Scholar
  • 54 Dantas Z N, Vicino M, Balmaceda J P, Asch R H, Stone S C. Comparison between nafarelin and leuprolide acetate for in vitro fertilization: preliminary clinical study.  Fertil Steril . 1994;  61 705-708
    PubMedGoogle Scholar
  • 55 Goldman J A, Dicker D, Feldberg D, Ashkenazi J, Voliowich I. A prospective randomized comparison of two gonadotrophin-releasing hormone agonists, nafarelin acetate and buserelin acetate, in in-vitro fertilization-embryo transfer.  Hum Reprod . 1994;  9 226-228
    PubMedGoogle Scholar
  • 56 Lockwood G M, Pinkerton S M, Barlow D H. A prospective randomized single-blind comparative trial of nafarelin acetate with buserelin in long-protocol gonadotrophin-releasing hormone analogue controlled in-vitro fertilization cycles.  Hum Reprod . 1995;  10 293-298
    PubMedGoogle Scholar
  • 57 Oyesanya O A, Teo S K, Quah E, Abdurazak N, Lee F Y, Cheng W C. Pituitary down-regulation prior to in-vitro fertilization and embryo transfer: a comparison between a single dose of Zoladex depot and multiple daily doses of Suprefact.  Hum Reprod . 1995;  10 1042-1044
    PubMedGoogle Scholar
  • 58 Tanos V, Friedler S, Shushan A, Strauss N, Hetsroni I, Lewin A. Comparison between nafarelin acetate and D-Trp6-LHRH for temporary pituitary suppression in in vitro fertilization (IVF) patients: a prospective crossover study.  J Assist Reprod Genet . 1995;  12 715-719
    PubMedGoogle Scholar
  • 59 Avrech O M, Goldman G A, Pinkas H. Intranasal nafarelin versus buserelin (short protocol) for controlled ovarian hyperstimulation before in vitro fertilization: a prospective clinical trial.  Gynecol Endocrinol . 1996;  10 165-170
    PubMedGoogle Scholar
  • 60 Corson S L, Gutmann J N, Batzer F R, Gocial B. A double-blind comparison of nafarelin and leuprolide acetate for down-regulation in IVF cycles.  Int J Fertil Menopausal Stud . 1996;  41 446-449
    PubMedGoogle Scholar
  • 61 Westergaard L G, Erb K, Laursen S B, Rex S, Rasmussen P E. Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study.  Fertil Steril . 2001;  76 543-549
    CrossrefPubMedGoogle Scholar
  • 62 Wong J M, Forrest K A, Snabes S Z, Zhao S Z, Gersh G E, Kennedy S H. Efficacy of nafarelin in assisted reproductive technology: a meta-analysis.  Hum Reprod Update . 2001;  7 92-101
    CrossrefPubMedGoogle Scholar
  • 63 Zorn J R, Boyer P, Guichard A. Never on a Sunday: programming for IVF-ET and GIFT.  Lancet . 1987;  1 385-386
    PubMedGoogle Scholar
  • 64 Pellicer A, Simon C, Miro F. Ovarian response and outcome of in-vitro fertilization in patients treated with gonadotrophin-releasing hormone analogues in different phases of the menstrual cycle.  Hum Reprod . 1989;  4 285-289
    PubMedGoogle Scholar
  • 65 Daya S. Gonadotrophin-releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles (Cochrane Review). In: The Cochrane Library, Issue 1 Oxford: Update Software; 2000
    Google Scholar
  • 66 Kondaveeti-Gordon U, Harrison R F, Barry-Kinsella C, Gordon A C, Drudy L, Cottell E. A randomized prospective study of early follicular or midluteal initiation of long protocol gonadotropin-releasing hormone in an in vitro fertilization program.  Fertil Steril . 1996;  66 582-586
    PubMedGoogle Scholar
  • 67 Ron-El R, Herman A, Golan A, van der Ven H, Caspi E, Diedrich K. The comparison of early follicular and midluteal administration of long-acting gonadotropin-releasing hormone agonist.  Fertil Steril . 1990;  54 233-237
    PubMedGoogle Scholar
  • 68 San Roman A G, Surrey E S, Judd H L, Kerin J F. A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization.  Fertil Steril . 1992;  58 744-749
    PubMedGoogle Scholar
  • 69 Chang S Y, Lee C L, Wang M L. No detrimental effects in delaying initiation of gonadotropin administration after pituitary desensitization with gonadotropin-releasing hormone agonist.  Fertil Steril . 1993;  59 183-186
    PubMedGoogle Scholar
  • 70 Abdalla H I, Baber R J, Leonard T. Timed oocyte collection in an assisted conception programme using GnRH analogue.  Hum Reprod . 1989;  4 927-930
    PubMedGoogle Scholar
  • 71 Dimitry E S, Oskarsson T, Conaghan J, Margara R, Winston R M. Beneficial effects of a 24 h delay in human chorionic gonadotrophin administration during in-vitro fertilization treatment cycles.  Hum Reprod . 1991;  6 944-946
    PubMedGoogle Scholar
  • 72 Tan S L, Brinsden P. The use of luteinising hormone releasing hormone agonists for ovarian stimulation in assisted reproductive technology.  Ann Acad Med Singapore . 1992;  21 504-509
    PubMedGoogle Scholar
  • 73 Tan S L. Luteinizing hormone-releasing hormone agonists for ovarian stimulation in assisted reproduction.  Curr Opin Obstet Gynecol . 1994;  6 166-172
    PubMedGoogle Scholar
  • 74 Gonen Y, Jacobson W, Casper R F. Gonadotropin suppression with oral contraceptives before in vitro fertilization.  Fertil Steril . 1990;  53 282-287
    PubMedGoogle Scholar
  • 75 Kemeter P, Feichtinger W. Experience with a new fixed-stimulation protocol without hormone determinations for programmed oocyte retrieval for in-vitro fertilization.  Hum Reprod . 1989;  4 53-58
    PubMedGoogle Scholar
  • 76 Patton P E, Burry K A, Wolf D P, Kiessling A A, Craemer M J. The use of oral contraceptives to regulate oocyte retrieval.  Fertil Steril . 1988;  49 716-718
    PubMedGoogle Scholar
  • 77 Templeton A, van Look P, Lumsden M A. The recovery of pre-ovulatory oocytes using a fixed schedule of ovulation induction and follicle aspiration.  Br J Obstet Gynaecol . 1984;  91 148-154
    PubMedGoogle Scholar
  • 78 Jenkins J M. Cyst formation.  Hum Reprod . 1995;  10 3079-3080
    PubMedGoogle Scholar
  • 79 Keltz M D, Jones E E, Duleba A J, Polcz T, Kennedy K, Olive D L. Baseline cyst formation after luteal phase gonadotropin-releasing hormone agonist administration is linked to poor in vitro fertilization outcome.  Fertil Steril . 1995;  64 568-572
    PubMedGoogle Scholar
  • 80 Feldberg D, Ashkenazi J, Dicker D. Ovarian cyst formation: a complication of gonadotropin-releasing hormone agonist therapy.  Fertil Steril . 1989;  51 42-45
    PubMedGoogle Scholar
  • 81 Biljan M M, Mahutte N G, Dean N, Hemmings R, Bissonnette F, Tan S L. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues.  J Assist Reprod Genet . 1998;  15 599-604
    CrossrefPubMedGoogle Scholar
  • 82 Serafini P, Stone B, Kerin J, Batzofin J, Quinn P, Marrs R P. An alternate approach to controlled ovarian hyperstimulation in "poor responders": pretreatment with a gonadotropin-releasing hormone analog.  Fertil Steril . 1988;  49 90-95
    PubMedGoogle Scholar
  • 83 Damario M A, Barmat L, Liu H C, Davis O K, Rosenwaks Z. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.  Hum Reprod . 1997;  12 2359-2365
    CrossrefPubMedGoogle Scholar
  • 84 Barriere P, Lopes P, Boiffard J P. Use of GnRH analogues in ovulation induction for in vitro fertilization: benefit of a short administration regimen.  J In Vitro Fert Embryo Transf . 1987;  4 64-65
    PubMedGoogle Scholar
  • 85 Smitz J, Bollen N, Camus M, Devroey P, Wisanto A, Van Steirteghem C A. Short-term use of buserelin in combination with human menopausal gonadotrophins for ovarian stimulation for in-vitro fertilization in endocrinologically normal women.  Hum Reprod . 1990;  5 157-162
    PubMedGoogle Scholar
  • 86 Acharya U, Irvine S, Hamilton M, Templeton A. Prospective study of short and ultrashort regimens of gonadotropin-releasing hormone agonist in an in vitro fertilization program.  Fertil Steril . 1992;  58 1169-1173
    PubMedGoogle Scholar
  • 87 Howles C M, Macnamee M C, Edwards R G. Short term use of an LHRH agonist to treat poor responders entering an in-vitro fertilization programme.  Hum Reprod . 1987;  2 655-656
    PubMedGoogle Scholar
  • 88 Macnamee M C, Howles C M, Edwards R G, Taylor P J, Elder K T. Short-term luteinizing hormone-releasing hormone agonist treatment: prospective trial of a novel ovarian stimulation regimen for in vitro fertilization.  Fertil Steril . 1989;  52 264-269
    PubMedGoogle Scholar
  • 89 Martikainen H, Ronnberg L, Tapanainen J, Puistola U, Orava M, Kauppila A. Endocrine responses to gonadotrophins after LHRH agonist administration on cycle days 1-4: prevention of premature luteinization.  Hum Reprod . 1990;  5 246-249
    PubMedGoogle Scholar
  • 90 Sharma V, Williams J, Collins W, Riddle A, Mason B, Whitehead M. The sequential use of a luteinizing hormone-releasing hormone (LH-RH) agonist and human menopausal gonadotropins to stimulate folliculogenesis in patients with resistant ovaries.  J In Vitro Fert Embryo Transf . 1988;  5 38-42
    PubMedGoogle Scholar
  • 91 Corson S L, Batzer F R, Gocial B, Eisenberg E, Huppert L C, Nelson J R. Leuprolide acetate-prepared in vitro fertilization-gamete intrafallopian transfer cycles: efficacy versus controls and cost analysis.  Fertil Steril . 1992;  57 601-605
    PubMedGoogle Scholar
  • 92 de Ziegler D, Cedars M I, Randle D, Lu J K, Judd H L, Meldrum D R. Suppression of the ovary using a gonadotropin releasing-hormone agonist prior to stimulation for oocyte retrieval.  Fertil Steril . 1987;  48 807-810
    PubMedGoogle Scholar
  • 93 Pantos K, Meimeth-Damianaki T, Vaxevanoglou T, Kapetanakis E. Prospective study of a modified gonadotropin-releasing hormone agonist long protocol in an in vitro fertilization program.  Fertil Steril . 1994;  61 709-713
    PubMedGoogle Scholar
  • 94 Smitz J, Erard P, Camus M. Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol.  Hum Reprod . 1992;  7 1225-1229
    PubMedGoogle Scholar
  • 95 Smitz J, Van Den E A, Bollen N. The effect of gonadotrophin-releasing hormone (GnRH) agonist in the follicular phase on in-vitro fertilization outcome in normo-ovulatory women.  Hum Reprod . 1992;  7 1098-1102
    PubMedGoogle Scholar
  • 96 Hazout A, de Ziegler D, Cornel C, Fernandez H, Lelaidier C, Frydman R. Comparison of short 7-day and prolonged treatment with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation.  Fertil Steril . 1993;  59 596-600
    PubMedGoogle Scholar
  • 97 Yang T S, Tsan S H, Wang B C, Chang S P, Ng H T. The evaluation of a new 7-day gonadotropin-releasing hormone agonist protocol in the controlled ovarian hyperstimulation for in vitro fertilization.  J Obstet Gynaecol Res . 1996;  22 133-137
    PubMedGoogle Scholar
  • 98 Cedrin-Durnerin I, Bidart J M, Robert P, Wolf J P, Uzan M, Hugues J N. Consequences on gonadotrophin secretion of an early discontinuation of gonadotrophin-releasing hormone agonist administration in short-term protocol for in-vitro fertilization.  Hum Reprod . 2000;  15 1009-1014
    CrossrefPubMedGoogle Scholar
  • 99 Tolis G, Ackman D, Stellos A. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.  Proc Natl Acad Sci U S A . 1982;  79 1658-1662
    PubMedGoogle Scholar
  • 100 Schoemaker J, Scheele F, Broekmans F, Janssens R M. GnRH agonists: to dose or to overdose?. In: Shoham Z, Howles CM, Jacobs HS, eds. Female Infertility Therapy: Current Practice London: Martin Dunitz 1999: 169-170
    Google Scholar
  • 101 Janssens R M, Vermeiden J P, Lambalk C B, Schats R, Schoemaker J. Gonadotrophin-releasing hormone agonist dose-dependency of pituitary desensitization during controlled ovarian hyperstimulation in IVF.  Hum Reprod . 1998;  13 2386-2391
    CrossrefPubMedGoogle Scholar
  • 102 Lefebvre G. Comparison of two dosages of nafarelin nasal solution with hMG in a short protocol of ovarian stimulation for in vitro fertilization.  Nafarelin Recent Advances. London: Parthenon Publishing 1990: 15-21
    Google Scholar
  • 103 Polson D W, MacLachlan V, Krapez J A, Wood C, Healy D L. A controlled study of gonadotropin-releasing hormone agonist (buserelin acetate) for folliculogenesis in routine in vitro fertilization patients.  Fertil Steril . 1991;  56 509-514
    PubMedGoogle Scholar
  • 104 Simon A, Benshushan A, Shushan A. A comparison between a standard and reduced dose of D-Trp-6-luteinizing hormone-releasing hormone administered after pituitary suppression for in-vitro fertilization.  Hum Reprod . 1994;  9 1813-1817
    PubMedGoogle Scholar
  • 105 Sandow J, Donnez J. Clinical pharmakinetics of LHRH analogues. In: Brosens I, Jacobs HS, Runnebaum B, eds. LHRH Analogues in Gynaecology London: CRC Press-Parthenon Publishers 2002: 17-31
    Google Scholar
  • 106 Elgendy M, Afnan M, Holder R. Reducing the dose of gonadotrophin-releasing hormone agonist on starting ovarian stimulation: effect on ovarian response and in-vitro fertilization outcome.  Hum Reprod . 1998;  13 2382-2385
    CrossrefPubMedGoogle Scholar
  • 107 Takeuchi S, Minoura H, Shibahara T, Tsuiki Y, Noritaka F, Toyoda N. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection.  Fertil Steril . 2001;  76 532-537
    CrossrefPubMedGoogle Scholar
  • 108 Feldberg D, Farhi J, Ashkenazi J, Dicker D, Shalev J, Ben Rafael Z. Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels.  Fertil Steril . 1994;  62 343-346
    PubMedGoogle Scholar
  • 109 Olivennes F, Righini C, Fanchin R. A protocol using a low dose of gonadotrophin-releasing hormone agonist might be the best protocol for patients with high follicle-stimulating hormone concentrations on day 3.  Hum Reprod . 1996;  11 1169-1172
    PubMedGoogle Scholar
  • 110 Fleming R, Black W P, Coutts J R. Effects of LH suppression in polycystic ovary syndrome.  Clin Endocrinol (Oxf) . 1985;  23 683-688
    PubMedGoogle Scholar
  • 111 Dodson W C, Hughes C L, Whitesides D B, Haney A F. The effect of leuprolide acetate on ovulation induction with human menopausal gonadotropins in polycystic ovary syndrome.  J Clin Endocrinol Metab . 1987;  65 95-100
    PubMedGoogle Scholar
  • 112 Homburg R, Kilborn J, West C, Jacobs H S. Treatment with pulsatile luteinizing hormone-releasing hormone modulates folliculogenesis in response to ovarian stimulation with exogenous gonadotropins in patients with polycystic ovaries.  Fertil Steril . 1990;  54 737-739
    PubMedGoogle Scholar
  • 113 Weise H C, Fiedler K, Kato K. Buserelin suppression of endogenous gonadotropin secretion in infertile women with ovarian feedback disorders given human menopausal/human chorionic gonadotropin treatment.  Fertil Steril . 1988;  49 399-403
    PubMedGoogle Scholar
  • 114 Buckler H M, Healy D L, Burger H G. Does gonadotropin suppression result in follicular development in premature ovarian failure?.  Gynecol Endocrinol . 1993;  7 123-128
    PubMedGoogle Scholar
  • 115 Scheele F, Hompes P G, van der M M, Schoute E, Schoemaker J. The effects of a gonadotrophin-releasing hormone agonist on treatment with low dose follicle stimulating hormone in polycystic ovary syndrome.  Hum Reprod . 1993;  8 699-704
    PubMedGoogle Scholar
  • 116 Vegetti W, Testa G, Ragni G, Parazzini F, Crosignani P G. Ovarian stimulation with low-dose pure follicle-stimulating hormone in polycystic ovarian syndrome anovulatory patients: effect of long-term pretreatment with gonadotrophin-releasing hormone analogue.  Gynecol Obstet Invest . 1998;  45 186-189
    CrossrefPubMedGoogle Scholar
  • 117 Eshel A, Abdulwahid N A, Armar N A, Adams J M, Jacobs H S. Pulsatile luteinizing hormone-releasing hormone therapy in women with polycystic ovary syndrome.  Fertil Steril . 1988;  49 956-960
    PubMedGoogle Scholar
  • 118 Filicori M, Flamigni C, Dellai P. Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles.  J Clin Endocrinol Metab . 1994;  79 1215-1220
    CrossrefPubMedGoogle Scholar
  • 119 Shoham Z, Homburg R, Jacobs H S. Induction of ovulation with pulsatile GnRH.  Baillieres Clin Obstet Gynaecol . 1990;  4 589-608
    PubMedGoogle Scholar
  • 120 Hughes E, Collins J, Vandekerckhove P. Gonadothrophin-releasing hormone analogue as an adjunct to gonadotropin therapy for clomiphene-resistant polycystic ovarian syndrome (Cochrane review). In: The Cochrane Library, Issue 4 Oxford: Update Software; 2002
    Google Scholar
  • 121 Dor J, Shulman A, Levran D, Ben Rafael Z, Rudak E, Mashiach S. The treatment of patients with polycystic ovarian syndrome by in-vitro fertilization and embryo transfer: a comparison of results with those of patients with tubal infertility.  Hum Reprod . 1990;  5 816-818
    PubMedGoogle Scholar
  • 122 Homburg R, Berkowitz D, Levy T, Feldberg D, Ashkenazi J, Ben Rafael Z. In vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome.  Fertil Steril . 1993;  60 858-863
    PubMedGoogle Scholar
  • 123 MacDougall M J, Tan S L, Balen A, Jacobs H S. A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization.  Hum Reprod . 1993;  8 233-237
    PubMedGoogle Scholar
  • 124 Fleming R, Coutts J R. LHRH analogues for ovulation induction, with particular reference to polycystic ovary syndrome.  Baillieres Clin Obstet Gynaecol . 1988;  2 677-687
    PubMedGoogle Scholar
  • 125 Abdalla H I, Ahuja K K, Leonard T, Morris N N, Honour J W, Jacobs H S. Comparative trial of luteinizing hormone-releasing hormone analog/human menopausal gonadotropin and clomiphene citrate/human menopausal gonadotropin in an assisted conception program.  Fertil Steril . 1990;  53 473-478
    PubMedGoogle Scholar
  • 126 Jacobs H S. Polycystic ovaries and polycystic ovary syndrome.  Gynecol Endocrinol . 1987;  1 113-131
    PubMedGoogle Scholar
  • 127 Ben Rafael Z, Bider D, Dan U, Zolti M, Levran D, Mashiach S. Combined gonadotropin releasing hormone agonist/human menopausal gonadotropin therapy (GnRH-a/hMG) in normal, high, and poor responders to hMG.  J In Vitro Fert Embryo Transf . 1991;  8 33-36
    PubMedGoogle Scholar
  • 128 Jenkins J M, Davies D W, Devonport H. Comparison of "poor" responders with "good" responders using a standard buserelin/human menopausal gonadotrophin regime for in-vitro fertilization.  Hum Reprod . 1991;  6 918-921
    PubMedGoogle Scholar
  • 129 Land J A, Yarmolinskaya M I, Dumoulin J C, Evers J L. High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome.  Fertil Steril . 1996;  65 961-965
    PubMedGoogle Scholar
  • 130 Muasher S J. Treatment of low responders.  J Assist Reprod Genet . 1993;  10 112-114
    PubMedGoogle Scholar
  • 131 Padilla S L, Dugan K, Maruschak V, Shalika S, Smith R D. Use of the flare-up protocol with high dose human follicle stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders.  Fertil Steril . 1996;  65 796-799
    PubMedGoogle Scholar
  • 132 Tasdemir M, Tasdemir I, Kodama H, Fukuda J, Tanaka T. Short protocol of gonadotropin releasing hormone agonist administration gave better results in long protocol poor-responders in IVF-ET.  J Obstet Gynaecol Res . 1996;  22 73-77
    PubMedGoogle Scholar
  • 133 Yang J H, Wu M Y, Chao K H, Chen S U, Ho H N, Yang Y S. Long GnRH-agonist protocol in an IVF program: is it appropriate for women with normal FSH levels and high FSH/LH ratios?.  J Reprod Med . 1997;  42 663-668
    PubMedGoogle Scholar
  • 134 Gelety T J, Pearlstone A C, Surrey E S. Short-term endocrine response to gonadotropin-releasing hormone agonist initiated in the early follicular, midluteal, or late luteal phase in normally cycling women.  Fertil Steril . 1995;  64 1074-1080
    PubMedGoogle Scholar
  • 135 Loumaye E, Vankrieken L, Depreester S, Psalti I, De Cooman S, Thomas K. Hormonal changes induced by short-term administration of gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in vitro fertilization and their consequences for embryo development.  Fertil Steril . 1989;  51 105-111
    PubMedGoogle Scholar
  • 136 Fasouliotis S J, Simon A, Laufer N. Evaluation and treatment of low responders in assisted reproductive technology: a challenge to meet.  J Assist Reprod Genet . 2000;  17 357-373
    PubMedGoogle Scholar
  • 137 Scott R T, Navot D. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization.  Fertil Steril . 1994;  61 880-885
    PubMedGoogle Scholar
  • 138 Fisch B, Royburt M, Pinkas H. Augmentation of low ovarian response to superovulation before in vitro fertilization following priming with contraceptive pills.  Isr J Med Sci . 1996;  32 1172-1176
    PubMedGoogle Scholar
  • 139 Abramov Y, Elchalal U, Schenker J G. Severe OHSS-an "epidemic" of severe OHSS: a price we have to pay?.  Hum Reprod . 1999;  14 2181-2183
    CrossrefPubMedGoogle Scholar
  • 140 Forman R G, Frydman R, Egan D, Ross C, Barlow D H. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention.  Fertil Steril . 1990;  53 502-509
    PubMedGoogle Scholar
  • 141 Golan A, Ron-El R, Herman A, Weinraub Z, Soffer Y, Caspi E. Ovarian hyperstimulation syndrome following D-Trp-6 luteinizing hormone-releasing hormone microcapsules and menotropin for in vitro fertilization.  Fertil Steril . 1988;  50 912-916
    PubMedGoogle Scholar
  • 142 Maroulis G B, Emery M, Verkauf B S, Saphier A, Bernhisel M, Yeko T R. Prospective randomized study of human menotropin versus a follicular and a luteal phase gonadotropin-releasing hormone analog-human menotropin stimulation protocols for in vitro fertilization.  Fertil Steril . 1991;  55 1157-1164
    PubMedGoogle Scholar
  • 143 Navot D, Bergh P A, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment.  Fertil Steril . 1992;  58 249-261
    PubMedGoogle Scholar
  • 144 Gerris J, De Vits A, Joostens M, Van Royen E. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).  Hum Reprod . 1995;  10 56-62
    CrossrefPubMedGoogle Scholar
  • 145 Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes J M. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist.  Fertil Steril . 1991;  56 213-220
    PubMedGoogle Scholar
  • 146 Shalev E, Geslevich Y, Ben Ami M. Induction of pre-ovulatory luteinizing hormone surge by gonadotrophin-releasing hormone agonist for women at risk for developing the ovarian hyperstimulation syndrome.  Hum Reprod . 1994;  9 417-419
    PubMedGoogle Scholar
  • 147 Aboulghar M A, Mansour R T, Serour G I, Amin Y, Abbas A M, Salah I M. Ovarian superstimulation and intrauterine insemination for the treatment of unexplained infertility.  Fertil Steril . 1993;  60 303-306
    PubMedGoogle Scholar
  • 148 Chaffkin L M, Nulsen J C, Luciano A A, Metzger D A. A comparative analysis of the cycle fecundity rates associated with combined human menopausal gonadotropin (hMG) and intrauterine insemination (IUI) versus either hMG or IUI alone.  Fertil Steril . 1991;  55 252-257
    PubMedGoogle Scholar
  • 149 Cohlen B J, Vandekerckhove P, te Velde R E, Habbema J D. Timed intercourse versus intra-uterine insemination with or without ovarian hyperstimulation for subfertility in men (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2002
    Google Scholar
  • 150 DiMarzo S J, Kennedy J F, Young P E, Hebert S A, Rosenberg D C, Villanueva B. Effect of controlled ovarian hyperstimulation on pregnancy rates after intrauterine insemination.  Am J Obstet Gynecol . 1992;  166 1607-1612
    PubMedGoogle Scholar
  • 151 Nulsen J C, Walsh S, Dumez S, Metzger D A. A randomized and longitudinal study of human menopausal gonadotropin with intrauterine insemination in the treatment of infertility.  Obstet Gynecol . 1993;  82 780-786
    PubMedGoogle Scholar
  • 152 Peterson C M, Hatasaka H H, Jones K P, Poulson Jr M A, Carrell D T, Urry R L. Ovulation induction with gonadotropins and intrauterine insemination compared with in vitro fertilization and no therapy: a prospective, nonrandomized, cohort study and meta-analysis.  Fertil Steril . 1994;  62 535-544
    PubMedGoogle Scholar
  • 153 Dodson W C, Haney A F. Controlled ovarian hyperstimulation and intrauterine insemination for treatment of infertility.  Fertil Steril . 1991;  55 457-467
    PubMedGoogle Scholar
  • 154 Sengoku K, Tamate K, Takaoka Y, Morishita N, Ishikawa M. A randomized prospective study of gonadotrophin with or without gonadotrophin-releasing hormone agonist for treatment of unexplained infertility.  Hum Reprod . 1994;  9 1043-1047
    PubMedGoogle Scholar
  • 155 Kim C H, Cho Y K, Mok J E. Simplified ultralong protocol of gonadotrophin-releasing hormone agonist for ovulation induction with intrauterine insemination in patients with endometriosis.  Hum Reprod . 1996;  11 398-402
    PubMedGoogle Scholar
  • 156 Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R. Thet use of a GnRH antagonist (cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg.  Hum Reprod . 1998;  13 2411-2414
    CrossrefPubMedGoogle Scholar
  • 157 Diedrich K, Diedrich C, Santos E. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist cetrorelix during ovarian stimulation.  Hum Reprod . 1994;  9 788-791
    PubMedGoogle Scholar
  • 158 The Ganirelix Dose-Finding Study Group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon).  Hum Reprod . 1998;  13 3023-3031
    CrossrefPubMedGoogle Scholar
  • 159 Obruca A, Fischl F, Huber J. Programming oocyte retrieval using oral contraceptive pretreatment before ovarian stimulation with a GnRH antagonist (Cetrotide) protocol.  Hum Reprod . 2001;  16(Abstract book 1) 89
    PubMedGoogle Scholar
  • 160 Naether O GJ, Sterzik K, Strehler E. Cetrotide and Gonal-F in IVF/ICSI patients receiving oral contraceptives for cycle programming prior to IVF/ICSI.  Gynecol Endocrinol . 2001;  12 (12)
    PubMedGoogle Scholar
  • 161 Van Loenen C D A, Huirne J AF, Schats R, Donnez J, Lambalk C B. An open label multicentre randomised parallel controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and an GnRH-antagonist in patients undergoing an ART (IVF/ICSI)-treatment.  Hum Reprod . 2001;  16(Abstract book 1) 144
    PubMedGoogle Scholar
  • 162 de Jong D, Macklon N S, Fauser B C. A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the "follicle-stimulating hormone window" combined with the gonadotropin-releasing hormone antagonist cetrorelix.  Fertil Steril . 2000;  73 1051-1054
    CrossrefPubMedGoogle Scholar
  • 163 Rongieres-Bertrand C, Olivennes F, Righini C. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (cetrorelix): a pilot study with minimal stimulation.  Hum Reprod . 1999;  14 683-688
    CrossrefPubMedGoogle Scholar
  • 164 Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P. Comparison of different doses of gonadotropin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation.  Fertil Steril . 1997;  67 917-922
    CrossrefPubMedGoogle Scholar
  • 165 Gordon K, Danforth D R, Williams R F, Hodgen G D. New trends in combined use of gonadotropin-releasing hormone antagonists with gonadotropins or pulsatile gonadotropin-releasing hormone in ovulation induction and assisted reproductive technologies.  Curr Opin Obstet Gynecol . 1992;  4 690-696
    PubMedGoogle Scholar
  • 166 Dubourdieu S, Le Nestour E, Spitz I M, Charbonnel B, Bouchard P. The combination of gonadotrophin-releasing hormone (GnRH) antagonist and pulsatile GnRH normalizes luteinizing hormone secretion in polycystic ovarian disease but fails to induce follicular maturation.  Hum Reprod . 1993;  8 2056-2060
    PubMedGoogle Scholar
  • 167 de Jong D, Macklon N S, Mannaerts B M, Coelingh Bennink H J, Fauser B C. High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization.  Hum Reprod . 1998;  13 573-575
    CrossrefPubMedGoogle Scholar
  • 168 Albano C, Felberbaum R E, Smitz J. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.  Hum Reprod . 2000;  15 526-531
    CrossrefPubMedGoogle Scholar
  • 169 Borm G, Mannaerts B. The European Orgulatran Study Group. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial.  Hum Reprod . 2000;  15 1490-1498
    CrossrefPubMedGoogle Scholar
  • 170 The European and Middle East Orgulatran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation.  Hum Reprod . 2001;  16 644-651
    CrossrefPubMedGoogle Scholar
  • 171 Fluker M, Grifo J, Leader A. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation.  Fertil Steril . 2001;  75 38-45
    CrossrefPubMedGoogle Scholar
  • 172 Craft I, Gorgy A, Hill J, Menon D, Podsiadly B. Will GnRH antagonists provide new hope for patients considered "difficult responders" to GnRH agonist protocols?.  Hum Reprod . 1999;  14 2959-2962
    CrossrefPubMedGoogle Scholar
  • 173 Nikolettos N, al Hasani S, Felberbaum R. Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders.  Eur J Obstet Gynecol Reprod Biol . 2001;  97 202-207
    CrossrefPubMedGoogle Scholar
  • 174 Akman M A, Erden H F, Tosun S B, Bayazit N, Aksoy E, Bahceci M. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial.  Hum Reprod . 2001;  16 868-870
    CrossrefPubMedGoogle Scholar
  • 175 Akman M A, Erden H F, Tosun S B, Bayazit N, Aksoy E, Bahceci M. Addition of GnRH antagonist in cycles of poor responders undergoing IVF.  Hum Reprod . 2000;  15 2145-2147
    CrossrefPubMedGoogle Scholar
  • 176 Ragni G, Vegetti W, Baroni E. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.  Hum Reprod . 2001;  16 2258-2262
    CrossrefPubMedGoogle Scholar
  • 177 Olivennes F, Belaisch-Allart J, Emperaire J C. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).  Fertil Steril . 2000;  73 314-320
    CrossrefPubMedGoogle Scholar
  • 178 Al-Inany H, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception (Cochrane Review). In: The Cochrane Library, Issue 1 Oxford: Update Software; 2002
    Google Scholar
  • 179 Ashton W T, Sisco R M, Kieczykowski G R. Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and functional activity.  Bioorg Med Chem Lett . 1999;  9 2597-2602
    PubMedGoogle Scholar
      >